Romanoff A, et al. - Whether inflammatory breast cancer (IFLBC) carries a higher locoregional recurrence (LRR) risk and worse outcomes vs other T4 lesions was determined by comparing the outcomes of patients with IFLBC vs patients with non-IFLBC who were treated with modern multimodality therapy (neoadjuvant chemotherapy, mastectomy, and radiation therapy) between 2006 and 2016. Between these patient groups, recurrences and survival were assessed both overall and stratified by receptor subtype. Similar outcomes with modern multimodality therapy were seen among patients with IFLBC and patients with non-IFLBC; isolated LRR was not common. In patients with IFLBC, poor outcomes were observed in relation to the triple-negative (TN) subtype, and this suggests the need for new treatment approaches in this group.